Pathobiomes in Gut of Critically Ill Patients

Last updated: February 11, 2025
Sponsor: University of Chicago
Overall Status: Active - Recruiting

Phase

N/A

Condition

Pressure Ulcers

Treatment

P. aeruginosa using in vitro and in vivo assays

Clinical Study ID

NCT06822465
16494B
5R01GM062344-23
  • Ages 18-85
  • All Genders
  • Accepts Healthy Volunteers

Study Summary

Despite powerful antibiotics, 50% of the intestinal tracts of critically ill surgical patients are colonized by Pseudomonas aeruginosa, whose mere presence in this site increases mortality fourfold by mechanisms that remain unknown. Many patients who survive the initial surgical trauma still succumb to multi-organ failure and septicemia secondary to an invasive nosocomial infection. The sequelae of shock, hypoxia, and parental nutrition result in injury to the intestinal mucosa, changes in gut permeability, and failure of intestinal defense mechanisms. These conditions put patients at risk for infection and multiple organ failure secondary to the translocation of enteric bacteria, initiating a systemic release of inflammatory mediators-a process that has been termed gut-derived sepsis.

Intestinal P. aeruginosa senses host factors released during stress and responds by activating its virulence gene machinery. As such, the presence of a highly activating intestinal milieu serves to induce virulence in strains of P. aeruginosa and this correlates to the severity of a patient's illness. While the host-pathogen interaction is a dynamic process, the study expects that as a patient's illness worsens or resolves over time, the "virulence-activating" properties of their intestinal milieu will change accordingly. This study will conduct a prospective observational trial in a population of critically ill patients at the Universtiy of Chicago Medical Center. This trial will entail collecting and screening stool samples obtained from critically ill patients for their virulence inducing capabilities on laboratory strains of P. aeruginosa using in vitro and in vivo assays. The study also plans to isolate strains of intestinal P. aeruginosa from stool samples to determine the prevalence of intestinal P. aeruginosa in a population of critically ill patients.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Any ethnicity

  • Age > 18 years and < 85 years

Exclusion

Exclusion Criteria:

  • A known history of HIV/AIDS

  • Active pregnancy

  • Are incarcerated will be excluded from the study.

Study Design

Total Participants: 100
Treatment Group(s): 1
Primary Treatment: P. aeruginosa using in vitro and in vivo assays
Phase:
Study Start date:
December 19, 2024
Estimated Completion Date:
December 31, 2029

Connect with a study center

  • The University of Chicago

    Hyde Park, Illinois 60637
    United States

    Active - Recruiting

Map preview placeholder

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.